A Phase 3, Open-label, Randomized Parallel,2-arm,Multi-center Study Of Talazoparib(Bmn 673) Versus Physician's Choice In Germline Brca Mutation Subjects With Locally Advanced And/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens For Metastatic Disease

Trial Profile

A Phase 3, Open-label, Randomized Parallel,2-arm,Multi-center Study Of Talazoparib(Bmn 673) Versus Physician's Choice In Germline Brca Mutation Subjects With Locally Advanced And/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens For Metastatic Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Talazoparib (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
  • Indications Advanced breast cancer; Carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms EMBRACA
  • Sponsors BioMarin Pharmaceutical; Medivation; Pfizer
  • Most Recent Events

    • 27 Feb 2018 Planned End Date changed from 1 Dec 2019 to 27 Dec 2019.
    • 29 Jan 2018 Planned End Date changed from 27 Dec 2019 to 1 Dec 2019.
    • 12 Dec 2017 According to a Myriad Genetics media release, data from this trial were presented last week at the 2017 San Antonio Breast Cancer Symposium (SABCS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top